DJ Affluent Medical announces coverage initiation of its stock by Gilbert Dupont - Société Générale Group.
Affluent Medical
Affluent Medical announces coverage initiation of its stock by Gilbert Dupont - Société Générale Group.
04-Apr-2024 / 17:45 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
PRESS RELEASE
Affluent Medical announces coverage initiation
of its stock by Gilbert Dupont - Société Générale Group
Aix-en-Provence, 4 April 2024 - 5:45 pm - Affluent Medical (ISIN: FR0013333077 - Ticker: AFME), a French clinical-phase
MedTech company specializing in the international development and industrialization of innovative medical prostheses,
announces today that Gilbert Dupont - Société Générale Group has initiated coverage of its stock.
Gilbert Dupont - Société Générale Group began covering the stock with a study entitled "Un pour tous, tous pour un" ("
one for all and all for one"), published on 3 April 2024. In this study, Gilbert Dupont - Société Générale Group
recommended buying the stock, with a target price of EUR3.30, representing a potential upside of 89% compared with the
closing price on 2 April 2024.
This initiation completes the coverage of Affluent Medical's stock and adds to the financial analyst consensus
alongside Invest Securities, Kepler Cheuvreux, Portzamparc BNP Paribas Group, and TP ICAP Midcap.
About Affluent Medical
Affluent Medical is a French MedTech company, founded by Truffle Capital, with the ambition to become a global leader
in the treatment of structural heart diseases, which are the world's leading cause of mortality, and urinary
incontinence, which currently affects one in four adults.
Affluent Medical develops next-generation, mini-invasive, innovative, adjustable, and biomimetic implants to restore
critical physiological functions. The product candidates developed by the Company are currently all in clinical
studies.
Subject to raising the necessary funds to finance its strategy and to positive results from ongoing clinical studies,
the Company's ambition is to gradually commercialize its products early 2026.
For more information, visit www.affluentmedical.com
Contacts:
AFFLUENT MEDICAL SEITOSEI.ACTIFIN
Financial communications / press relations
Sébastien Ladet Ghislaine GASPARETTO / Jennifer JULLIA
Chief Executive Officer +33 (0)6 21 10 49 24 / +33 (0)1 56 88 11 19
investor@affluentmedical.com ghislaine.gasparetto@seitosei-actifin.com / jennifer.jullia@seitosei-actifin.com
MC SERVICES AG
PRIMATICE
Media relations Europe
Media relations France
Thomas Roborel de Climens Caroline Bergmann / Kirsten RÜHL
+33 (0)6 78 12 97 95
+49 (0)211 529252 20 / +49 (0)211 529252 16
thomasdeclimens@primatice.com
affluent@mc-services.eu
-----------------------------------------------------------------------------------------------------------------------
Regulatory filing PDF file File: 20240404_Affluent Medical_PR_SOCGEN coverage initiation
=------------------------------------------------------------------
Language: English
Company: Affluent Medical
320 avenue Archimède, Les pléiades III Bâtiment B
13100 Aix en Provence France
France
Phone: +33 4 42 95 12 20
E-mail: jerome.geoffroy@affluentmedical.com
Internet: https://www.affluentmedical.com/
ISIN: FR0013333077
Euronext Ticker: AFME
AMF Category: Inside information / Other releases
EQS News ID: 1873727
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
1873727 04-Apr-2024 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1873727&application_name=news
(END) Dow Jones Newswires
April 04, 2024 11:45 ET (15:45 GMT)
